POLR2I (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:5438, HGNC:9196, MIM:180662, NM_006233, NP_006224, POLR2I, RNA polymerase II subunit I, RPB9, hRPB14.5

Omim:OMIM:180662

Id:ENSG00000105258

Hgnc:HGNC:9196

Entrez:5438

Ensembl:ENSG00000105258

Description:RNA polymerase II subunit I

This gene encodes a subunit of RNA polymerase II, the polymerase responsible for synthesizing messenger RNA in eukaryotes. This subunit, in combination with two other polymerase subunits, forms the DNA binding domain of the polymerase, a groove in which the DNA template is transcribed into RNA. The product of this gene has two zinc finger motifs with conserved cysteines and the subunit does possess zinc binding activity. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View POLR2I's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with POLR2I.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using POLR2I.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for POLR2I.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with POLR2I.

Results found

Linked to

	Label	Description
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146612 2 V 0 AMIODARONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE230634 PARP inhibition 0 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 5 V 4 VERTEPORFIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE104022 1 V 0 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE193541 nifurtimox A-549 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128076 doxycycline HEK293 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE146612 2 V 0 AMIODARONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE230634 PARP inhibition 0 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE151090 5 V 4 VERTEPORFIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE104022 1 V 0 TAMOXIFEN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE193541 nifurtimox A-549 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE128076 doxycycline HEK293 1 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.